{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:50:16Z","timestamp":1749703816251},"reference-count":51,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14557","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T12:25:13Z","timestamp":1720095913000},"source":"Crossref","is-referenced-by-count":1,"title":["BTK acts as a modulator of the response to imatinib in chronic myeloid leukemia"],"prefix":"10.3892","volume":"28","author":[{"given":"Lena","family":"Schmidlechner","sequence":"first","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig\u2011Holstein, Campus Kiel, D\u201124105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Nagel","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig\u2011Holstein, Campus Kiel, D\u201124105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Vater","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University Hospital Schleswig\u2011Holstein, Campus Kiel, D\u201124105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingolf","family":"Cascorbi","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig\u2011Holstein, Campus Kiel, D\u201124105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Kaehler","sequence":"additional","affiliation":[{"name":"Institute of Experimental and Clinical Pharmacology, University Hospital Schleswig\u2011Holstein, Campus Kiel, D\u201124105 Kiel, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"key20240805083200_b1-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"key":"key20240805083200_b2-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343.h8003343_3343_3356","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"key20240805083200_b3-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"key20240805083200_b4-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20240805083200_b5-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"key20240805083200_b6-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"key20240805083200_b7-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"key20240805083200_b8-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic myeloid leukemia: Mechanisms of resistance and treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20240805083200_b9-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"key20240805083200_b10-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20240805083200_b11-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and resistance to BCR-ABL1-targeted therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"key20240805083200_b12-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"696960","DOI":"10.3389\/fphar.2021.696960","article-title":"Pharmacogenomics of impaired tyrosine kinase inhibitor response: Lessons learned from chronic myelogenous leukemia","volume":"12","author":"Kaehler","year":"2021","journal-title":"Front Pharmacol"},{"key":"key20240805083200_b13-ol-28-3-14557","first-page":"86","article-title":"The Importance of mutational analyses in chronic myeloid leukaemia for treatment choice","volume":"4","author":"de Lavallade","year":"2016","journal-title":"Eur Med J Oncol"},{"key":"key20240805083200_b14-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","article-title":"Molecular pathways: BCR-ABL","volume":"18","author":"Cilloni","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20240805083200_b15-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3892\/or.2022.8355","article-title":"Genome-wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor-resistant CML cells","volume":"48","author":"Kaehler","year":"2022","journal-title":"Oncol Rep"},{"key":"key20240805083200_b16-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1200897","DOI":"10.3389\/fonc.2023.1200897","article-title":"Clonal evolution in tyrosine kinase inhibitor-resistance: Lessons from in vitro-models","volume":"13","author":"Kaehler","year":"2023","journal-title":"Front Oncol"},{"key":"key20240805083200_b17-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"Inhibitors targeting Bruton's tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"key20240805083200_b18-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"key20240805083200_b19-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/bies.950181009","article-title":"X-linked agammaglobulinemia (XLA): A genetic tyrosine kinase (Btk) disease","volume":"18","author":"Mattsson","year":"1996","journal-title":"Bioessays"},{"key":"key20240805083200_b20-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"key20240805083200_b21-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"2040620721989586","DOI":"10.1177\/2040620721989586","article-title":"Current and novel BTK inhibitors in Waldenstrom's macroglobulinemia","volume":"12","author":"Ntanasis-Stathopoulos","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"key20240805083200_b22-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: Biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"},{"key":"key20240805083200_b23-ol-28-3-14557","first-page":"223","article-title":"Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: Review of current evidence and future directions","volume":"17","author":"Bond","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20240805083200_b24-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.2021.39.15_suppl.7500","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20240805083200_b25-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","article-title":"Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial","volume":"41","author":"Hillmen","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20240805083200_b26-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1182\/blood.V45.3.321.bloodjournal453321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"key20240805083200_b27-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.exphem.2021.05.006","article-title":"ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells","volume":"99","author":"Kaehler","year":"2021","journal-title":"Exp Hematol"},{"key":"key20240805083200_b28-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20240805083200_b29-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"92018","DOI":"10.18632\/oncotarget.21272","article-title":"MicroRNA-212\/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells","volume":"8","author":"Kaehler","year":"2017","journal-title":"Oncotarget"},{"key":"key20240805083200_b30-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1002\/jcb.27885","article-title":"Retinoic acid-induced survival effects in SH-SY5Y neuroblastoma cells","volume":"120","author":"Waetzig","year":"2019","journal-title":"J Cell Biochem"},{"key":"key20240805083200_b31-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1124\/mol.119.116590","article-title":"Alternative polyadenylation of ABC transporters of the C-family (ABCC1, ABCC2, ABCC3) and implications on posttranscriptional Micro-RNA regulation","volume":"97","author":"Bruhn","year":"2020","journal-title":"Mol Pharmacol"},{"key":"key20240805083200_b32-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13073-021-00835-9","article-title":"CADD-Splice-improving genome-wide variant effect prediction using deep learning-derived splice scores","volume":"13","author":"Rentzsch","year":"2021","journal-title":"Genome Med"},{"key":"key20240805083200_b33-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"7360","DOI":"10.1038\/ncomms8360","article-title":"Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury","volume":"6","author":"Ito","year":"2015","journal-title":"Nat Commun"},{"key":"key20240805083200_b34-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"650414","DOI":"10.3389\/fcell.2021.650414","article-title":"Targeting solid tumors with BTK inhibitors","volume":"9","author":"Uckun","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20240805083200_b35-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic landscape of waldenstrom macroglobulinemia and its impact on treatment strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20240805083200_b36-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"689472","DOI":"10.3389\/fimmu.2021.689472","article-title":"Resistance mutations to BTK inhibitors originate from the NF-\u03baB but not from the PI3K-RAS-MAPK Arm of the B cell receptor signaling pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Front Immunol"},{"key":"key20240805083200_b37-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"687458","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton's tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol"},{"key":"key20240805083200_b38-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"key":"key20240805083200_b39-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"key20240805083200_b40-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/humu.22791","article-title":"Characterization of all possible single-nucleotide change caused amino acid substitutions in the kinase domain of Bruton tyrosine kinase","volume":"36","author":"V\u00e4liaho","year":"2015","journal-title":"Hum Mutat"},{"key":"key20240805083200_b41-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1046\/j.1365-3083.2001.00967.x","article-title":"Analysis of Btk mutations in patients with X-linked agammaglobulinaemia (XLA) and determination of carrier status in normal female relatives: A nationwide study of Btk deficiency in Greece","volume":"54","author":"Speletas","year":"2001","journal-title":"Scand J Immunol"},{"key":"key20240805083200_b42-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"key20240805083200_b43-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"5845","DOI":"10.3390\/jcm10245845","article-title":"Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience","volume":"10","author":"Broccoli","year":"2021","journal-title":"J Clin Med"},{"key":"key20240805083200_b44-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20240805083200_b45-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41375-020-0977-8","article-title":"Therapeutic inhibition of Fc\u03b3RIIb signaling targets leukemic stem cells in chronic myeloid leukemia","volume":"34","author":"Parting","year":"2020","journal-title":"Leukemia"},{"key":"key20240805083200_b46-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/ccr3.974","article-title":"Concomitant imatinib and ibrutinib in a patient with chronic myelogenous leukemia and chronic lymphocytic leukemia","volume":"5","author":"Shea","year":"2017","journal-title":"Clin Case Rep"},{"key":"key20240805083200_b47-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/leu.2008.126","article-title":"Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells","volume":"22","author":"MacPartlin","year":"2008","journal-title":"Leukemia"},{"key":"key20240805083200_b48-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clinl Pharmacokinet"},{"key":"key20240805083200_b49-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: A gene-expression profiling approach","volume":"20","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"key":"key20240805083200_b50-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"727531","DOI":"10.3389\/fcell.2021.727531","article-title":"Multifaceted immunomodulatory effects of the BTK inhibitors ibrutinib and acalabrutinib on different immune cell subsets-beyond B lymphocytes","volume":"9","author":"Zhu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"key20240805083200_b51-ol-28-3-14557","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41419-018-1122-8","article-title":"BTK: A two-faced effector in cancer and tumour suppression","volume":"9","author":"Rada","year":"2018","journal-title":"Cell Death Dis"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T05:32:09Z","timestamp":1722835929000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,7,4]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14557","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"article-number":"424"}}